



IFW

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: October 20, 2004

By: Jennifer L. Mahoney
Jennifer L. Mahoney

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Soos, *et al.*

APPLICATION No.: 10/694,247

FILED: December 27, 2003

FOR: ORALLY-ADMINISTERED INTERFERON-
TAU COMPOSITIONS AND METHODS

EXAMINER: Not yet Assigned

ART UNIT: 1648

CONF. No.: 4066

**Information Disclosure Statement Within Three Months of
Application Filing or Before First Action – 37 CFR 1.97(b)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 CFR 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

- ☒ Copies of the following references can be found in parent U.S. Application No. 08/616,904:
 - ☒ All cited references except U.S. Patent No. 6,372,206
- ☒ Copies of the following reference can be found in parent U.S. Application No. 10/029,890:
 - ☒ U.S. Patent No. 6,372,206

3. Effect of Information Disclosure Statement (37 CFR 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due because this Information Disclosure Statement is being filed before the mailing date of the first Office Action.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 CFR 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,

Date: 10/20/04

Judy M. Mohr
Judy M. Mohr
Registration No. 38,563

Correspondence Address:

Customer No. 22918
(650) 838-4300



INFORMATION DISCLOSURE CITATION

Form PTO-1449 (Modified)

(Use several sheets if necessary)

Page 1 of 2

ATTY. DOCKET NO.

55600.8003.US01

SERIAL NO.

10/694,247

APPLICANT

Soos, et al.

FILING DATE

December 27, 2003

GROUP

1648

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	4,997,646	03/05/91	Hansen, et al.			
	5,019,382	05/28/91	Cummins, Jr.			
	5,206,219	04/27/93	Desai			
	5,372,808	12/13/94	Blatt, et al.			
	5,705,363	01/06/98	Imakawa			
	6,372,206	04/2002	Soos, et al.			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
WO 90/09806	09/07/90	PCT			
WO 94/10313	05/11/94	PCT			
WO 95/27499	10/19/95	PCT			
WO 95/27502	10/19/95	PCT			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	Amidon, G.L., et al., <i>Peptide and Protein Drug Delivery</i> 43:146-152 (1998).
	Anonymous, <i>Lancet</i> 336(8720):935 (1990).
	Aranason, et al., <i>Clinical Neuropharmacology</i> 17(16):495-547, (1994).
	Banga, A.K., "Oral Delivery of Peptide and Protein Drugs," (Chapter 8) in <i>THERAPEUTIC PEPTIDES AND PROTEINS: FORMULATION, PROCESSING, AND DELIVERY SYSTEMS</i> , Technomic Publishing Co., Inc., Lancaster, PA, pp. 217-243 (1995).
	Brod, S.A., and Burns, D.K., <i>Neurology</i> 44:1144-1148 (1994).
	Brod, S.A., et al., <i>J. Interferon Res.</i> 15:115-122 (1995).
	Brod, S., et al., <i>J of Interferon and Cytokine Research</i> 15(2):115-122 (1995).
	Brod, S. and Khan, M., <i>J of Autoimmunity</i> 9(1):11-20 (1996).
	Caban, J., et al., <i>Archivum Immunologiae et Therapiae Experimentalis</i> 41(3-4):229-235 (1993).
	Cummins, J.M., et al., <i>Veterinary Immunology and Immunopathology</i> 45(3-4):355-60 (1995).
	Cummins, J.M., <i>J. Biol. Response Modif</i> 7(5):513-523 (1988).
	Degre, M. and Bukholm, G., <i>J of Biological Regulators and Homeostatic Agents</i> 9(1):15-20 (1995).

INFORMATION DISCLOSURE CITATION Form PTO-1449 (Modified) (Use several sheets if necessary) Page 2 of 2		ATTY. DOCKET NO.	SERIAL NO.
		55600.8003.US01	10/694,247
		APPLICANT <div style="text-align: center;">Soos, et al.</div>	
		FILING DATE December 27, 2003	GROUP 1648

	Dermer, G.B., <i>Bio/Technology</i> 12:320, (1994).
	Fleischmann, W., et al., <i>Proceedings of the Society for Experimental Biology and Medicine</i> 201(2):200-7 (1992).
	Freshney, R.I., <i>CULTURE OF ANIMAL CELLS: A MANUAL OF BASIC TECHNIQUE</i> , Alan R. Liss, Inc., NY, NY, pages 3-4, (1983).
	Georgiades, J.A., <i>Archivum Immunologiae et Therapiae Experimentalis</i> 44(1):11-22 (1996).
	Georgiades, J.A., <i>Archivum Immunologiae et Therapiae Experimentalis</i> 41(3-4):259-265 (1993).
	Hutchinson, V.A., et al., <i>Mol Biother</i> 2(3):160-164 (1990).
	Imakawa, K., et al., <i>Nature</i> , 330:377-379, (1987).
	Johnson, H.M., et al., <i>Scientific American</i> 270(5):40-47 (1994).
	Koren, S., et al., <i>Proceedings of the Society for Experimental Biology and Medicine</i> 204(2):155-164 (1993).
	Lecce, J.G., et al., <i>Mol Biother</i> 2(4):211-216 (1990).
	Moore, B., et al., <i>Veterinary Immunology and Immunopathology</i> 49(4):347-358 (1996).
	Nelson, P.A., et al., <i>Annals of the New York Academy of Sciences</i> , 778:145-155 (1996).
	Pontzer, C.H., et al., <i>Biochem. Biophys. Res. Commun.</i> , 152(2):801-807, (1988).
	Pontzer, C.H., et al., <i>Cancer Research</i> 51:5304-5307 (1991).
	Qi, Y., et al., <i>Hum Antibod Hybridomas</i> 7(1):21-26 (1996).
	Ranade, V.V. and Hollinger, M.A., <i>DRUG DELIVERY SYSTEMS</i> , CRC Press Inc. Boca Raton, Florida pp. 127-128, 151 (1996).
	Shiozawa, K., et al., <i>Arthritis & Rheumatism</i> 39(9):S63 (1996).
	Soos, J.M., and Johnson, H.M., <i>J. Interferon Res.</i> 15:39-45 (1995).
	Soos, J.M., et al., <i>J. Immunol.</i> 155:2747-2753 (1995).
	Soos, J.M., et al., <i>FASEB J. Experimental Biol.</i> 9(4):Abs. No. 5940 (1995).
	Weiss, R.C., et al., <i>J. Am. Vet. Med. Assoc.</i> 199(10):1477-1481 (1991).
	Wills, R.J., et al., <i>Journal of Interferon Research</i> 4(3):399-409 (1984).
	Witt, P., et al., <i>J of Interferon Research</i> 12(6):411-413 (1992).
	Zielinska, W., et al., <i>Archivum Immunologiae et Therapiae Experimentalis</i> 41(3-4):241-251 (1993).

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.